zonisamide has been researched along with Weight Reduction in 14 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events." | 9.16 | Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. ( Allison, DB; Bray, GA; Gadde, KM; Kopping, MF; Wagner, HR; Yonish, GM, 2012) |
| "Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = ." | 9.12 | Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. ( D'Alessio, DA; Guerdjikova, AI; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA, 2006) |
| "Zonisamide and bupropion have been investigated for weight reduction in obese adults." | 9.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
| "In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity." | 9.10 | Zonisamide for weight loss in obese adults: a randomized controlled trial. ( Franciscy, DM; Gadde, KM; Krishnan, KR; Wagner, HR, 2003) |
| " We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients." | 7.78 | Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012) |
| "Zonisamide has been associated with weight loss in children and adults." | 5.20 | Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy. ( Giorgi, L; Lagae, L; Meshram, C; Patten, A, 2015) |
| " Zonisamide inhibits carbonic anhydrase, and induces weight loss in obese patients." | 5.19 | Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study. ( Eskandari, D; Grote, L; Hedner, J; Karimi, M; Stenlöf, K; Zou, D, 2014) |
| "Zonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events." | 5.16 | Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. ( Allison, DB; Bray, GA; Gadde, KM; Kopping, MF; Wagner, HR; Yonish, GM, 2012) |
| "Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = ." | 5.12 | Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. ( D'Alessio, DA; Guerdjikova, AI; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA, 2006) |
| "Zonisamide and bupropion have been investigated for weight reduction in obese adults." | 5.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
| "In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity." | 5.10 | Zonisamide for weight loss in obese adults: a randomized controlled trial. ( Franciscy, DM; Gadde, KM; Krishnan, KR; Wagner, HR, 2003) |
| " We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients." | 3.78 | Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012) |
| "Drug-induced weight alteration can be a serious side effect that applies to several therapeutic agents and must be referred to in the respective approved labeling texts." | 2.48 | Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. ( Antel, J; Hebebrand, J, 2012) |
| "Median weight loss was 8kg (range: 2-16)." | 1.46 | Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers. ( Doğan, EA; Erdoğan, Ç; Genç, BO; Genç, E, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doğan, EA | 1 |
| Genç, E | 1 |
| Genç, BO | 1 |
| Erdoğan, Ç | 1 |
| Eskandari, D | 1 |
| Zou, D | 1 |
| Karimi, M | 1 |
| Stenlöf, K | 1 |
| Grote, L | 1 |
| Hedner, J | 1 |
| Lagae, L | 1 |
| Meshram, C | 1 |
| Giorgi, L | 1 |
| Patten, A | 1 |
| Fujioka, K | 1 |
| Janszky, J | 1 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Kelemen, A | 1 |
| Rásonyl, G | 1 |
| Neuwirth, M | 1 |
| Barcs, G | 1 |
| Szucs, A | 1 |
| Jakus, R | 1 |
| Fabó, D | 1 |
| Juhos, V | 1 |
| Pálfy, B | 1 |
| Halász, P | 1 |
| Lim, J | 1 |
| Ko, YH | 1 |
| Joe, SH | 1 |
| Han, C | 1 |
| Lee, MS | 1 |
| Yang, J | 1 |
| Antel, J | 1 |
| Hebebrand, J | 1 |
| Kim, DW | 1 |
| Yoo, MW | 1 |
| Park, KS | 1 |
| Katz, MH | 1 |
| Gadde, KM | 3 |
| Kopping, MF | 1 |
| Wagner, HR | 3 |
| Yonish, GM | 2 |
| Allison, DB | 1 |
| Bray, GA | 1 |
| Franciscy, DM | 1 |
| Krishnan, KR | 1 |
| McElroy, SL | 1 |
| Kotwal, R | 1 |
| Guerdjikova, AI | 1 |
| Welge, JA | 1 |
| Nelson, EB | 1 |
| Lake, KA | 1 |
| D'Alessio, DA | 1 |
| Keck, PE | 1 |
| Hudson, JI | 1 |
| Foust, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zonisamide for Weight Reduction in Obese Adults[NCT00275834] | 225 participants (Actual) | Interventional | 2006-01-31 | Completed | |||
| Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients[NCT00221442] | Phase 3 | 60 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary endpoint was weight loss at 1-year, Month-12 weight minus baseline weight, in kilograms. (NCT00275834)
Timeframe: 1 year
| Intervention | kg (Mean) |
|---|---|
| Placebo | -4.0 |
| Zonisamide 200 mg | -4.4 |
| Zonisamide 400 mg | -7.3 |
C reactive Protein (CRP) (NCT00275834)
Timeframe: 1 year
| Intervention | mg/L (Mean) |
|---|---|
| Placebo | 0.523 |
| Zonisamide 200 mg | 0.536 |
| Zonisamide 400 mg | 0.443 |
This outcomes measure followed the same principles at measurement of proportions of patients with 5% weight loss described elsewhere. (NCT00275834)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Placebo | 6 |
| Zonisamide 200 mg | 17 |
| Zonisamide 400 mg | 24 |
These were the proportions of patients losing 5% or more weight at 1-year relative to baseline. The measures were modeled with logistic regressions that included the three-level group proxy and a baseline weight covariate. (NCT00275834)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Placebo | 23 |
| Zonisamide 200 mg | 26 |
| Zonisamide 400 mg | 41 |
Hospital Anxiety and Depression Scale - Depression (HADS-D) The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression. (NCT00275834)
Timeframe: 1 year
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.12 |
| Zonisamide 200 mg | 2.76 |
| Zonisamide 400 mg | 1.95 |
Analyses was based on intent-to-treat ANCOVA. Difference scores from baseline to endpoint (Month-12) for each measure were regressed on the three-level proxy denoting group while controlling for the baseline value of the same measure. Contrasts were subsequently estimated in models, which had a significant overall treatment effect. (NCT00275834)
Timeframe: 1 year
| Intervention | cm (Mean) |
|---|---|
| Placebo | -4.8 |
| Zonisamide 200 mg | -6.1 |
| Zonisamide 400 mg | -8.5 |
(NCT00275834)
Timeframe: Baseline, 1 year
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Placebo | -0.6 | -1.5 |
| Zonisamide 200 mg | -4.4 | -3.6 |
| Zonisamide 400 mg | -1.9 | -3.9 |
(NCT00275834)
Timeframe: baseline, 1 year
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| Total Cholesterol | LDL Cholesterol | HDL Cholesterol | Triglycerides | |
| Placebo | -1.9 | -2.0 | 2.5 | -11.3 |
| Zonisamide 200 mg | 4.1 | 1.7 | 1.5 | 0.7 |
| Zonisamide 400 mg | -0.1 | -0.3 | 3.4 | -11.7 |
3 reviews available for zonisamide and Weight Reduction
| Article | Year |
|---|---|
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem | 2015 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide.
Topics: Animals; Anticonvulsants; Drug Therapy, Combination; Fructose; Humans; Isoxazoles; Risk Assessment; | 2012 |
6 trials available for zonisamide and Weight Reduction
| Article | Year |
|---|---|
Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study.
Topics: Aged; Anthropometry; Body Mass Index; Body Weight; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase | 2014 |
Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Child; Epilepsies, Partial; Female; Humans; Isoxazoles | 2015 |
Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antioxidants; Body Mass Index; Dose-Response Relationship, Drug; Double-Bli | 2012 |
Zonisamide for weight loss in obese adults: a randomized controlled trial.
Topics: Adult; Anti-Obesity Agents; Anticonvulsants; Body Mass Index; Caloric Restriction; Combined Modality | 2003 |
Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.
Topics: Adult; Anticonvulsants; Body Mass Index; Bulimia; Dose-Response Relationship, Drug; Double-Blind Met | 2006 |
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Huma | 2007 |
5 other studies available for zonisamide and Weight Reduction
| Article | Year |
|---|---|
Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Tolerance; Epilepsies, Partial; Female; Huma | 2017 |
Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Confusion; Disorders of Excessive Somno | 2011 |
Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients.
Topics: Adult; Female; Humans; Isoxazoles; Male; Mental Disorders; Middle Aged; Outpatients; Overweight; Psy | 2011 |
Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; L | 2012 |
Zonisamide: no magic bullet.
Topics: Female; Humans; Isoxazoles; Male; Obesity; Weight Loss; Zonisamide | 2012 |